Evaluation of total serum bile acids concentration and bile acid profiles in healthy cats after oral administration of ursodeoxycholic acid.
Ursodeoxycholic acid (UDCA; 10 mg/kg of body weight) was administered orally to 5 healthy cats for 3 months. Signs of illness were not apparent in any cat during treatment with UDCA. Results of monthly CBC, serum biochemical analysis, and urinalysis were unchanged during drug administration. There was a decrease in serum cholesterol concentration in 4 cats. Total postprandial serum bile acids (PPSBA) concentration was significantly (P = 0.0003) increased over total preprandial serum bile acids (PRSBA) concentration at all sample collection periods. The PRSBA and PPSBA concentrations were significantly (P < 0.05) increased at all sample collection periods after administration of UDCA, compared with baseline values. Ursodeoxycholic and tauroursodeoxycholic acids were not detected in serum prior to initiating administration of UDCA. Both bile acids were detected in the serum of all cats 1 and 2 months after UDCA administration and were detected in the serum of 2 cats 3 months after initiating UCDA administration. Hepatic ultrasonographic findings were normal before and after completion of UDCA administration. A mild, focal lymphocytic infiltrate was observed in 3 cats 3 months after initiating UDCA administration. Results of the study indicate that UDCA is absorbed into the systemic circulation of cats after oral administration, undergoes hepatic conjugation, and appears to be safe.
Day
D G
DG
Animal Health Center, College of Veterinary Medicine, Mississippi State University 39762.
Meyer
D J
DJ
Johnson
S E
SE
Weisbrode
S E
SE
Thudium
D T
DT
Rhodes
D C
DC
D000284:Administration, Oral; D000818:Animals; D001647:Bile Acids and Salts / Q000097:blood*; D002415:Cats / Q000097:blood*; D005260:Female; D008297:Male; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*
D001647:Bile Acids and Salts; D014580:Ursodeoxycholic Acid